Want to see CH:COPN full AI Analyst Report?
COPN Stock Chart & Stats
CHF97.80
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF97.80
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF53.40 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.07B
Enterprise ValueCHF1.25B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Jul 23, 2026Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF145.00Price Target Upside48.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance SheetExtremely low leverage and substantial equity provide durable financial flexibility. This balance-sheet strength lets the company absorb revenue volatility, fund near-term R&D or regulatory steps without immediate financing, and preserves strategic optionality over the next 2–6 months.
Niche Specialty Focus In GastroenterologyA focused portfolio in gastroenterology/endoscopy builds durable competitive advantage via clinical specialization, established physician relationships, and regulatory know-how. This niche positioning supports repeatable product demand and partner interest over multiple quarters.
Proven Capacity For Strong Cash/profit GenerationThe company has demonstrated it can generate substantial operating and free cash in favorable years, evidencing scalable margins and effective commercialization. That capability indicates the business model can self-fund growth or return capital when revenue conditions normalize.
Bears Say
Sharp Revenue And Profitability Decline In 2025A severe year-over-year drop and swing to negative margins show earnings are highly cyclical and unpredictable. This undermines durable earnings visibility, complicates multi-quarter planning, and increases the risk that strong prior cash results are non-repeatable.
Recent Deterioration In Cash GenerationSwitching from large positive cash generation to cash burn within a year highlights vulnerability to revenue shocks. Persistent negative operating/free cash flow would force reliance on the balance sheet or external financing, limiting reinvestment and increasing structural funding risk.
Revenue Dependent On Partnering/licensing MilestonesA business model reliant on partner milestones and royalties tends to produce lumpy, timing-sensitive revenue. Dependence on external commercialization reduces control over sales execution and makes multi-period revenue and cash forecasts structurally less reliable.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF53.40 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.07B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 23, 2026 which is in 3 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.185 by -CHF0.277.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.942 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate is 0.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.185. Following the earnings report the stock price went down -10.522%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF145.00
▲(48.26% Upside)